InvestorsObserver
×
News Home

Crispr Therapeutics AG (CRSP) Stock: What Does the Chart Say Wednesday?

Wednesday, July 21, 2021 01:14 PM | InvestorsObserver Analysts

Mentioned in this article

Crispr Therapeutics AG (CRSP) Stock: What Does the Chart Say Wednesday?

Overall market sentiment has been down on Crispr Therapeutics AG (CRSP) stock lately. CRSP receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Crispr Therapeutics AG has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CRSP!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CRSP Stock Today?

Crispr Therapeutics AG (CRSP) stock is trading at $128.95 as of 1:08 PM on Wednesday, Jul 21, an increase of $4.81, or 3.87% from the previous closing price of $124.14. The stock has traded between $122.88 and $129.07 so far today. Volume today is light. So far 800,466 shares have traded compared to average volume of 1,489,948 shares. To see InvestorsObserver's Sentiment Score for Crispr Therapeutics AG click here.

More About Crispr Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need. Click Here to get the full Stock Report for Crispr Therapeutics AG stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App